- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03491735
Patterns of Glaucoma in Glaucoma Subspecialty Clinics in Egypt and India in the Year 2018
April 2, 2018 updated by: Rana H. Amin, Kasr El Aini Hospital
In this study, we are aiming to identify the patterns of glaucoma observed and treated at Glaucoma Subspecialty Clinics of Kasr Al-Aini Hospital, Cairo University in Cairo, Egypt and corresponding clinics in Sadguru Netra Chikitsalaya Post Graduate Institute of Ophthalmology in Mumbai, Maharashtra, India during the year 2018.
We are hoping that this study would provide an update on current statistics available on Indian population as well as provide novel numbers on the prevalence of glaucoma and its patterns in one of the largest tertiary care hospitals in Egypt.
These results will then be compared to patterns observed in other epidemiological studies done in other countries.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
2500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rana H Amin, M.Sc.
- Phone Number: 00201276020720
- Email: rana_hussein4@hotmail.com
Study Locations
-
-
-
Cairo, Egypt, 11562
- Recruiting
- Kasr Al-Aini Hospital, Cairo University
-
Contact:
- Rana H Amin, M.Sc.
- Phone Number: 00201276020720
- Email: rana_hussein4@hotmail.com
-
Contact:
- Ahmed M Abdel-Rahman, M.D.
- Phone Number: 00201227394861
- Email: ahmed.mostafa@kasralainy.edu.eg
-
Sub-Investigator:
- Rasha Mounir, M.D.
-
Sub-Investigator:
- Yasmine M. El-Sayed, M.D.
-
Sub-Investigator:
- Reham S. Allam, M.D.
-
Sub-Investigator:
- Mohammed Sabry, M.D.
-
-
-
-
-
Mumbai, India, 400020
- Recruiting
- two centres: Kasr Al-Aini Hospital in Cairo and Sadguru Netra Chikitsalaya Postgraduate Institute of Ophthalmology
-
Contact:
- Rakesh Shakya, M.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
All patients referred to and following up in the glaucoma sub-specialty clinics in the year 2018 in two centres: Kasr Al-Aini Hospital in Cairo and Sadguru Netra Chikitsalaya Postgraduate Institute of Ophthalmology in India
Description
Inclusion Criteria:
- All patients referred to glaucoma sub-specialty clinics in the year 2018 in two centres: Kasr Al-Aini Hospital in Cairo and Sadguru Netra Chikitsalaya Postgraduate Institute of Ophthalmology in India
Exclusion Criteria:
- Patients younger than 18 years old.
- Patients with incomplete examination data
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group A
Patients referred to glaucoma sub-specialty clinics in Kasr Al-Aini Hospital, Cairo University, Egypt in the year 2018
|
recording of patient data and its input into an excel sheet from which statistics will be derived
|
Group B
Patients referred to glaucoma sub-specialty clinics in Sadguru Netra Chikitsalaya Postgraduate Institute of Ophthalmology, Mumbai, India in the year 2018
|
recording of patient data and its input into an excel sheet from which statistics will be derived
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patterns of Glaucoma
Time Frame: 12 months starting january 1st, 2018 til December 31st, 2018
|
Determining patterns of glaucoma seen in one year in glaucoma sub-specialty clinics in two countries: Egypt and India
|
12 months starting january 1st, 2018 til December 31st, 2018
|
Demographic data
Time Frame: 12 months starting january 1st, 2018 til December 31st, 2018
|
Determining demographic data with respect to age and gender in different types of glaucoma in each country
|
12 months starting january 1st, 2018 til December 31st, 2018
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-glaucoma treatment
Time Frame: 12 months starting january 1st, 2018 til December 31st, 2018
|
Determining details of anti-glaucoma treatment used in each country
|
12 months starting january 1st, 2018 til December 31st, 2018
|
Positive family history
Time Frame: 12 months starting january 1st, 2018 til December 31st, 2018
|
Determining percentage of patients with positive family history in each country
|
12 months starting january 1st, 2018 til December 31st, 2018
|
Management decisions
Time Frame: 12 months starting january 1st, 2018 til December 31st, 2018
|
Determining different management decisions taken by doctors in each country
|
12 months starting january 1st, 2018 til December 31st, 2018
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2018
Primary Completion (Anticipated)
December 31, 2018
Study Completion (Anticipated)
December 31, 2018
Study Registration Dates
First Submitted
April 2, 2018
First Submitted That Met QC Criteria
April 2, 2018
First Posted (Actual)
April 9, 2018
Study Record Updates
Last Update Posted (Actual)
April 9, 2018
Last Update Submitted That Met QC Criteria
April 2, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12CM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
statistics obtained from data collected
IPD Sharing Time Frame
january 1st 2018 til december 31st 2018
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on collection of data from patient files
-
University Hospital, Basel, SwitzerlandCompletedDegenerative Lumbar Spine DiseasesSwitzerland
-
Murielle SurquinCompleted
-
Hospital Galdakao-UsansoloHospital Donostia; Hospital de Basurto; Hospital Universitario de Canarias; Hospital... and other collaboratorsCompleted
-
Tamas IllesCompleted
-
Brugmann University HospitalCompleted
-
Brugmann University HospitalCompletedCovid19Belgium, Italy, France
-
Dr Philippe CLEVENBERGHCompleted
-
Agnieszka PozdzikCompleted
-
Pierre WauthyCompleted